COVID-19: Immune Perspective and Current Treatment Strategies

Muhammad Awais¹, Muhammad Naveed¹, Sajid Mansoor², Rimsha Zafar¹, Rabia Riaz¹
1. Department of Biotechnology, Faculty of Life Sciences, University of Central Punjab, Lahore, Pakistan
2. Department of Microbiology, Faculty of Life Sciences, University of Central Punjab, Lahore, Pakistan

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as

doi: https://doi.org/10.32350/BSR.0304.06

Abstract

Coronavirus disease 2019 (COVID-19) is now a well-established and a lethal respiratory pandemic, affecting millions with about 10% fatality rate. Infected patients show mild to severe symptoms that may manifest as mild fever, cough, headache and nausea or they may even remain asymptomatic. World Health Organization has reported over 245,373,039 confirmed cases worldwide with 4,979,421 deaths (October 2021). There are myriads of promising approaches to pharmacologically treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the newly reported seventh human coronavirus, which is responsible for this pandemic. Various types of potential drugs; monoclonal antibodies, interferon therapies, peptides, small molecule drugs,
oligonucleotides and vaccines are under consideration and target various structural components of the virus. A strong host immune system is a key player in combating COVID-19 along with the effective vaccines that are a game-changing tool. The focus of the review is some worth mentioning drug candidates; remdesivir, lopinavir, emetine, aloxistatin, viracept, homoharringtonine, ivermectin, favipiravir, tocilizumab, chloroquine and leronlimab against COVID-19 infections, targeting the membrane nucleocapsid, spike or envelope proteins, either currently in clinical trials or under consideration. Many drugs directly inhibit the viral infection while others trigger the immune system to fight against the virus. Furthermore, we also discussed the current covid vaccines; Pfizer, Moderna, etc. from different technical lines for immunization. Therefore, here we review how the immune system tries to manage the infection as well as vaccines and some of the potential therapeutic agents.

**Keywords**

SARS-CoV-2; COVID-19; Innate immune response; Adaptive immune response; Therapeutic drugs; Vaccine.

**Abbreviations**

Acute respiratory distress syndrome (ARDS), Coronavirus (CoV), Coronavirus disease 2019 (COVID-19), C reactive protein (CRP), Endoplasmic reticulum (ER), Granulocyte-colony stimulation factor (GCSF), Interferon (IFN), Interferon regulatory factor (IRF), Interleukin (IL), Immunoglobulin (Ig), Interferon stimulated genes (ISGs), Janus kinase-signal transducer and activator of transcription (JAK-STAT), Macrophage inflammatory protein alpha (MIP1α), Monocyte chemotactic protein (MCP), the Middle East Respiratory Syndrome (MERS), NOD-like receptors (NLR), Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκβ), Natural
killer cells (NK), Pattern association molecular patterns (PAMPs), Pattern recognition receptors (PRR), Personal protective equipment (PPE), Severe acute respiratory syndrome-Coronavirus 2 (SARS-CoV-2), Toll like receptor (TLR), Tyrosine protein kinase (TYK), T helper type 1 cell (Th1), World health organization (WHO).
1. Introduction

Coronaviruses (CoVs), the largest RNA enveloped viruses with crown-like spikes belong to the *Coronaviridae* family [1]. These are important pathogens to humans and vertebrates. To date, six coronaviruses have been reported to cause respiratory diseases including common cold CoVs (NL63, OC43, HKU1 and 229E) and highly pathogenic CoVs (MERS-CoV and SARS-CoV) [2]. Previously, two major epidemics of human coronavirus (HCoV) were reported including Severe Acute Respiratory Syndrome (SARS) in 2002 with 10% fatality rate [3] and Middle East Respiratory Syndrome (MERS) in 2012 with 39% fatality rate [4]. A novel coronavirus, severe acute respiratory coronavirus 2 (SARS-CoV-2), originated in Wuhan, China [5], found in association with coronavirus disease 2019 (COVID-19). This infection is a respiratory syndrome of the lower respiratory tract, characterized by dry cough, fever, tiredness, sore throat, nausea and less frequently diarrhea [6]. Clinically, pneumonia is the preliminary feature, however, RNAemia and acute respiratory distress syndrome (ARDS) are also observed in critical patients.

COVID-19 outbreak was massive and spread over the globe at an alarming rate. In February 2020, the World Health Organization (WHO) declared it as a public health emergency of international concern [7]. WHO reported 245,373,039 confirmed cases with 4,979,421 deaths till October 2021[8]. The incidence of acquiring disease directly correlates with age and associated comorbidities including obesity, diabetes mellitus, cardiovascular diseases, hypertension, pulmonary disorder, or renal disease [9]. Approximately, the percentage of mortality for younger with this disease is approaching to 7% and 55% for patients older than 60 years [10, 11]. A study comprising 140 COVID-19 patients has reported approximately equal chances (1:1 ratio) of disease in males and females [12]. The following review summarizes the structural features,
immune perspective and potential therapeutic treatment strategies against SARS-CoV-2, along with topical status of vaccination against this ailment.

2. SARS-CoV-2; etiology, genomics and morphology

After entry, the incubation period for SARS-CoV-2 ranges between 5 to 7 days, while 14 days were also reported in some patients [13]. COVID-19 could be categorized into mild, moderate, severe and critical diseases. The majority of the patients (81%) represented mild disease which is categorized by mild fever, sore throat, nasal congestion, muscle ache and malaise without radiographic features. Moderate ones mostly possess tachypnea and shortness of breath while severe cases exhibit sepsis and respiratory distress syndrome (ARDS) which is the leading cause of mortality [14]. Patients with the critical condition have shown respiratory failure, cardiac injury, RNAemia, septic shock, or multiple organ dysfunction [15, 16].

Elevated prothrombin time, creatine kinase, C-reactive protein (CRP), D-dimer and ALT with lymphopenia (CD4 and CD8) [15] are the common clinical findings in COVID-19 sufferers. Some severe patients of corona exhibit high leucocyte and neutrophil-lymphocyte ratio (NLR) with a lower percentage of basophils, eosinophils and monocytes [17]. Furthermore, patients with intensive care unit (ICU) exhibit markedly increased profile of interleukin (IL)-6, IL-2, IL-10, IL-8 (chemokine), interferon gamma-induced protein 10 (IP10), granulocyte colony-stimulating factor (GCSF), monocyte chemotactic protein 1 (MCP1), macrophages inflammatory protein alpha (MIP1A) and tumor necrosis factor (TNF)-α [2, 18]. However, COVID-19 non-survivors have shown elevated ferritin, IL-6, neutrophil count, blood urea, D-dimer and creatinine phosphate [19]. Anti-52 kDa S6SA/Ro antibody, anti-60 kDa SSA/Ro antibody and antinuclear antibodies
were also found prevalent in patients. Ground-glass opacity and bilateral patchy shadowing on chest CT-scan are other important clinical findings [21].

SARS-CoV-2 contains the largest positive-sense RNA genome ranges between 26 to 32kb with a 5’-methyl cap and 3’poly-A tail [22]. Full-length genome sequencing of SARS-CoV-2 revealed 88.99% [23] and 79.5% sequence similarity with SARS-like coronaviruses and SARS-CoV, respectively [24]. The genome of the mature virus is associated with phosphorylated nucleocapsid (N) protein and encased in phospholipid bilayer envelope with embedded spike glycoprotein trimmer (S), hemagglutinin-esterase, membrane (M) protein and envelope (E) protein as shown in Figure 1 [1]. Among these, E protein increases the pathogenicity as it is involved in the assembly and release of viruses [25]. Besides these structural proteins, different CoVs also synthesize other structural proteins including HE protein, 3a/b protein and 4a/b protein [26].

**Figure 1. Structure of SARS-CoV-2**

The structure is comprised of positive-sense ssRNA encased in the lipid bilayer, having four structural proteins including S-E-M-N.

The figure is made with BioRender (https://app.biorender.com/)
S protein homotrimers make up the spikes of SARS-CoV-2 which bind with an angiotensin-converting enzyme (ACE)-2 receptors for host cell entry [20]. Afterward, conformational changes in S protein promote the fusion of the viral envelope with the host cell membrane. The virus inoculates its RNA genome into the cell where it is translated into polyproteins as shown in Figure 2. Viral proteinases break down the polyproteins into smaller protein products. During discontinuous transcription, genomic mRNAs are produced and translated into viral proteins. Genomic RNA and viral polyproteins are assembled in the endoplasmic reticulum (ER) and Golgi apparatus, from where they are released in the extracellular milieu [6].

It has been observed that infection due to corona primarily begins with particular binding of its spike S protein to the cells’ entry receptors, whose tissue distribution and expression impacts the viral pathogenicity and tropism. Worth mentioning examples include; angiotensin-converting enzyme 2 (ACE2; SARS-CoV, SARS-CoV-2 and HCoV-NL63), aminopeptidase N (APN; HCoV-229E) and dipeptidyl peptidase 4 (DPP4; MERS-CoV).

Moreover, to enhance the therapeutic and prophylactic activities against COVID-19, a deeper understanding of the pathobiology of the virus is of immense importance. As mentioned above Receptor Binding Domain (RBD) of the spike (S) protein is used by the SARS-CoV-2 to bind with ACE2 of the host to enter into the human cell [27]. It is the functional receptor of the outbreak and in fact the structural homology and highly genomic similarity among the S proteins of SARS-CoV-2 and previously known SARS-CoV helped to locate the contact residues that interacting with ACE2. It was similar to SARS-CoV and was also found to be conserved not only in SARS-CoV-2 but also in other members of the species of SARS-CoV [28]. Apart from this, priming of the virus S protein demands the cellular transmembrane serine protease2 (TMPRSS2) that is expressed in the respiratory tract of humans and dominantly assists in the entry of pathogens including SARS-
CoV. Non essentially, the entry can also be assisted through lysosomal/endosomal cysteine proteases cathepsin L and B (CTSL, CTSB). Moreover, in vitro analysis revealed that hindrance of all three proteases inhibits the entry of SARS-CoV while in the case of SARS-CoV-2, suppression of TMPRSS2 was sufficient to prevent its entry into primary lung cells and lung cell lines [28].

More recently, a distinct feature of the S protein of SARS-CoV-2 was identified as the presence of polybasic cleavage site (PRRAR) at the S1-S2 boundary. This acquisition is efficiently cleaved by the prototype proprotein convertase furin that overcomes the species barrier and causes successful infection. This may also enhance the transmissibility along with the expansion of zoonotic potential and cell tropism [28]. After attachment and entry into the host cell, coronavirus now proceeds towards the translation of the replicase gene. For the cleavage of replicase polyproteins, the virus encodes a few proteases and to synthesize RNA, a suitable environment is generated by assembling myriads of non-structural proteins (nsps) (that consist of variable enzyme domains and functions) into the replicase-transcriptase complex (RTC) [29]. Furthermore, it has been observed that there are still various accessory and non-structural proteins present in the coronavirus but their functions and characteristics are not fully known. The discovery of their activity will improve the therapeutic targets to inhibit viral replication [29].
Figure 2. The life cycle of SARS-CoV-2 [6]

The life cycle of SARS-CoV-2 begins when S protein binds to the host cell receptor (ACE2). After that viral envelope fuses with the host cell membrane and the virus releases its genomic RNA into the host cell where it is translated into polyproteins which are then broken down into smaller protein products. During discontinuous transcription, sub-genomic mRNAs are produced by polymerases and then translated into viral proteins. In the Golgi apparatus and ER, genomic RNA and viral proteins are assembled into virions, which are then released out of the host cell.

3. Immunology and novel coronavirus (SARS-CoV-2)

The immune system is the key player in combating coronavirus-related infections [1]. Recent studies have suggested that SARS-CoV-2 regulates both, humoral and cellular division of the immune system; suggesting their role in immune-mediated protection [30].
3.1. Innate immune response against SARS-CoV-2

At present, an assessment of immune response effectiveness against SARS-CoV-2 is not completely known. Interferon (IFN) type I, a component of innate division usually develops as an initial response against viral infections via controlling viral replication [31]. Response against the virus is initiated after a successful recognition of its invasion. In the case of RNA viruses like SARS-CoV-2, pathogen-associated molecular patterns (PAMPS) are recognized by endosomal RNA receptors, toll-like receptors (TLR3 and TLR7) and cytosolic RNA receptors like RIG-I. TLRs are mainly involved in the recognition of lipids, lipoproteins, proteins and nucleic acid of invading parasites at the cell membrane, endosomes and lysosomes [32]. Immediately, after recognition, the oligomerization of receptors regulates the downstream signaling cascade including regulatory transcription factors, most importantly the interferon regulatory factors (IRF3) and nuclear factors (NF)-kB [22]. This results in the expression of proinflammatory cytokines and type I IFN as the first line of defense. TLRs, RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs) are the main pattern recognition receptors (PRRs) which activates the downstream pathways for the IFNs production [33]. In response, type I IFN activates the Janus kinase signal transducer and activator of transcription (JAK-STAT) signaling pathway. Afterward, JAK1 and tyrosine kinase 2 (TYK2) phosphorylate the STAT1 and STAT2, which develops a complex with IRF9 to initiate the transcription of IFN stimulated gene (ISGs) [34]. The successful type I IFN ultimately suppresses the viral infection at an early stage as shown in Figure 3.
Figure 3. Host innate immune response against SARS-CoV-2

Attachment of virus to host cell is recognized by TLR3 & TLR7 and after recognition, oligomerization of receptors regulates the downstream signaling cascades including NF-kb and T signaling pathway. Afterward, JAK1 and TYK2 phosphorylate the STAT1 and STAT2, which IRF3 which results in the expression of type 1 IFN. In turn, type 1 IFN activates the JAK-STAT pathway and develops a complex with IRF9 to initiate the transcription of IFN stimulated genes (ISGs) that suppress the viral infection.

The figure is made with BioRender (https://app.biorender.com/)

IFNs, the main immunomodulatory molecules, inhibit viral spread by activating macrophages, natural killer (NK) cells and T and B lymphocytes. Structural and non-structural proteins of CoVs modulated IFN response for inhibiting the signaling pathway [1]. The genomic similarity of SARS-CoV-2 with SARS-CoV and MERS-CoV reveals the possibility of a similar mechanism for modulating the type I IFN response to downregulate the innate immune response [31]. Therefore, their inhibition put an imminent danger to the survival of the host [35]. Various cell and animal
models of SARS-CoV-2 infection exhibit a unique but inappropriate pattern of the inflammatory response which is characterized by the low level of type I and II IFNs. However, IL-6 and chemokines markedly increase. This significant reduction in innate antiviral response along with exuberant inflammatory cytokine production is the defining and deriving feature of COVID-19 [36].

Immunocompromised people, because of underlying morbidities including hypertension, cardiovascular disease and diabetes mellitus, are more susceptible to infection [37]. But a clear mechanism for the immune response against SARS-CoV-2 is yet to discover thoroughly.

3.2. Adaptive immune response against SARS-CoV-2

T helper type 1 cells (Th1) play a critical role in the adaptive immune response against viral infections. Among these, CD4+ T cells activate B cells for the immune response while CD8+ T cells exhibit cytotoxicity by killing virally infected cells [38, 39]. Production of antibodies and humoral immune response play an important role to prevent the cells from reinfection in the future. In contrast to the humoral immune response, the cellular immune response is another mechanism of adaptive immunity. It can be seen inside the infected cells, which is mediated by the T-lymphocytes [40].

SARS-CoV-2 enters the host cell via the ACE2 cell receptor. Attachment of virus is sensed by the endosomal TLR7 as shown in Fig 4 [41]. Activation of TLR7 leads to the production of α-IFN, TNFα, IL-6 and IL-12 which results in the activation of CD8+ cytotoxic T cells and CD4+ helper T cells. Then these T cells lead to the production of antibodies and antigen-specific B cells as shown in Figure 4. This type of adaptive immunity plays a critical role in combating viral infection. In the case of immunocompromised patients, the body is unable to produce an adequate adaptive
immune response against the virus due to which severe conditions occur that cause damaging attacks to the body e.g. ARDS, cytokine storm, failure of body organs and even death [42]. With aging, the number of naïve T cells shrinks, which means that the ability of the immune system to react against the pathogen also decreases. In contrast, children have a huge population of naïve T cells ready to fight against viruses [43]. This can be one of the explanations for more severe cases of COVID-19 among elders.

![Host adaptive immune response against SARS-CoV-2](https://app.biorender.com/)

**Fig.4 Host adaptive immune response against SARS-CoV-2**

SARS-CoV-2 enters the host cell and activates the endosomal TLR7 which results in the production of αIFN, TNFα, IL-6 and IL-12. In response, it activates the CD8+ & CD4+ T cells which leads to the production of antibodies and antigen-specific B cells that inhibit the viral infection.

The figure is made with BioRender (https://app.biorender.com/)

For SARS-CoV, seroconversion was seen on the 4th day after the onset of the disease. Neutralizing antibodies and Immunoglobin G (IgG) were reported in patients as long as after 2 years of infection
In the case of MERS-CoV, seroconversion was observed after 2 to 3 weeks of the onset of disease [45]. Infected patients showed high production of Immunoglobulin M (IgM) on the 9th day of infection, while on the 2nd week, a peak of Immunoglobulin G (IgG) is observed [23]. Invitro studies have shown that all sera from the patients of COVID-19 were able to neutralize the novel coronavirus [46].

In the case of SARS-CoV, T cell response was highly investigated. According to a report, the response of CD8+ T cells was highly observed against SARS-CoV, while the dominant response of Th1 cells was observed against MERS-CoV [47]. Furthermore, neutrophils also have a destructive role against many infections, but their function remains unanswered in the case of human coronaviruses [31].

Current studies showed that Th1 cell response is a key factor for successful control of SARS-CoV & MERS-CoV and probably true for SARS-CoV-2. Epitopes of B & T cells were extensively investigated for the structural proteins (S-E-M-N) of previously reported HCoVs [45]. If these epitopes can be identified in the case of SARS-CoV-2, it will be beneficial to create passive immunity by using the serum from recovered patients of COVID-19. It will also contribute to making a more effective vaccine against the HCoVs including SARS-CoV-2 [31]. In this regard, a vaccine platform based on DNA was chosen due to its ability to instigate both the humoral and cellular immune response along with its quick design and manufacturing property. Furthermore, investigations suggest that SARS-CoV-2 DNA vaccine candidates can elude the concerns of VAERD or vaccine-associated enhanced respiratory disease that is caused by Th2-bias vaccine modality, as it urges a balanced Th1/Th2 response [48]
4. Treatment strategies against SARS-CoV-2

Contemporary analysis and research are continuously inaugurating various treatment strategies for SARS-CoV-2 [49]. As in the present situation, there is no single antiviral therapy for CoVs instead there are only supportive treatments available. According to physicians and guidelines of WHO, the suspected individual should be quarantined in a room, while the confirmed ones should be isolated and cared for in the hospital or a room with personal protective equipment (PPE) [50]. Paracetamol and guaifenesin can be used as first-line treatment for fever and non-productive cough. Immunocompromised patients with other underlying diseases need to be hospitalized and should be treated with available effective drugs. Only a limited number of cases need to be admitted to ICU as soon as possible, due to the critical condition with severe symptoms e.g. shortness of breath [51]. They require immediate oxygen therapy to maintain the process of breathing.

Many of the drugs were proved effective against SARS-CoV and MERS-CoV. As SARS-CoV-2 is also a member of β-CoVs and has genomic similarity with SARS-CoV and MERS-CoV, so there might be a possibility that the same drugs could be effective against COVID-19. Remdesivir is an antiviral that was effective against SARS-CoV & MERS-CoV because it inhibits the transcription of viral RNA at an early stage [17]. Ribavirin is used against many viral infections including SARS & MERS as it inhibits the synthesis of viral RNA inside the host cell [52]. Griffithsin, a broad-spectrum antiviral agent targets the spike protein to inhibit the attachment of the virus to the host cell [53]. It is highly effective against many viruses including human CoVs. Rapamycin, Imatinib and Dasatinib are the antiviral drugs used to block the entry of viruses by inhibiting the kinase signaling pathways [54].
IFNs are the cytokines of innate immune response and can be expressed by various cell types after viral infection. Upon binding to the specific cell surface receptors, they activate the antiviral pathways to limit the spread of the virus [55]. But all the HCoVs can reduce the response of IFNs. So recombinant IFNs including α & β IFN can be the most effective therapeutic agents against SARS-CoV-2 as they induce the innate immune response against many viruses e.g. SARS-CoV [56, 57].

4.1. Direct therapeutic drugs against the virus

Some of the reported therapeutic drugs directly inhibit the viral infection inside the body. They mainly inhabit the viral replication and protein translation inside the host.

4.1.1. Remdesivir

It is an adenosine analog that was previously used against HCoVs including HCoV-229E, SARS-CoV, MERS-CoV and HCoV-OC43 [58, 59]. It inhibits viral replication at an early stage inside the host cell. The enzyme responsible for the RNA replication from an RNA template is known as RNA-dependent RNA polymerase (RdRp). It is also recognized as nsp-12 and is an indispensable part of RNA viruses as plays a crucial role in their life cycle [60]. In the case of SARS-CoV-1, nsp-7 and nsp-8 ensure the processivity of nsp-12 to perform its RNA-synthesizing activity. This tripartite polymerase complex along with nsp-14 performs the proofreading exonuclease activity.

It has been found that there exists a 96% sequence similarity between SARS CoV and SARS CoV-2 concerning RdRp [61]. So, agents targeting RdRp of SARS CoV are also expected to cover that of the SARS CoV-2’s [62]. Deeper analysis has revealed that remdesivir (GS-5734) acts as an RNA-dependent RNA polymerase (RdRp) binding substrate and metabolizes into an adenosine nucleotide analog (GS-441524) that further phosphorylates and converts into a nucleoside
triphosphate (NTP) to be taken as a substrate for SARS-CoV RdRp instead of ATP. Incorporation of these NTPs into viral replication machinery causes incompetent elongation. Hence, the substitution of ATP during polymerization causes chain termination without inhibiting the human mitochondrial RNA polymerases as well as human RNA Pol II [63]. Hence, the mechanism of action of the remdesivir—the nucleoside analog is to prevent the replication of the viral genome by targeting the RdRp enzyme [62]. It was previously tested for the treatment of hemorrhagic fever caused by the Ebola virus, but could not perform well during clinical trials [52, 64]. In December 2019, in-vitro experiments were performed to check the efficacy of Remdesivir against SARS-CoV-2, where the drug reduced the viral infection. In January 2020, it was first used successfully in COVID-19 patients [5]. It is currently in the fourth phase of the clinical trial for the treatment of this pandemic [19]. However, it is found to be effective as no side effects have been reported in patients till now.

4.1.2. Lopinavir

It is used with ritonavir and is known as an HIV protease inhibitor, approved by FDA [65]. Proteases aid in viral replication as they can cleave both structural and functional proteins, enabling the maturation of the virus. Lopinavir, a protease inhibitor can effectively inhibit viral replication to limit the spread of the virus [11]. It was used to treat SARS and MERS and found to be effective. But when used along with ritonavir, it showed many side effects in patients. Lopinavir and ritonavir in combination with or without ribavirin are under clinical trials to treat COVID-19. According to another report, lopinavir without ribavirin was effective against SARS-CoV-2 during in-vitro experiments [65].
4.1.3. Emetine

It is a protein synthesis inhibitor that has antiviral activity against many DNA and RNA viruses [66]. These include ebolavirus, rabies virus, zika virus, bovine herpesvirus 1, influenza virus and buffalo poxvirus [67–71]. It was effective to inhibit the replication of β-CoVs including HCoV-OC43, SARS-CoV, MERS-CoV and HCoV-NL63 [72]. Currently, it is under clinical trials for the treatment of COVID-19 [65]. Its general mechanism of action involves the hindrance of ribosomal protein synthesis. Emetine is found to prevent the polypeptide bond incorporation by inhibiting the transfer reaction of aminoacyl-sRNA [63].

4.1.4. Aloxistatin (E-64D)

This is a cysteine protease inhibitor of cathepsins and calpains and performs regulatory functions in cancer therapy and neurodegeneration. In the case of SARS-CoV-2, aloxistatin inhibits the viral entry by 92.3% as cathepsin L is an obligatory factor for coronavirus cell entry. Structural investigation of the drug revealed its interaction with the main protein (Mpro) of SARS-CoV-2, which is dominant for the synthesis of nonstructural proteins (NSP). Hence, it is considered a promising drug candidate to affect viral proteases [63].

4.1.5. Viracept (nelfinavir mesylate)

It is an anti-retroviral drug that is found to primarily inhibit HIV protease. Mechanistically, viracept targets the SARC-CoV-2 spike S glycoprotein and inhibits the S-o and S-n-mediated cell fusion. This indicates the drug's potential to prevent viral spread and transfer from one cell to another along with its enhanced sensitivity towards neutralizing antibodies [63].
4.1.6. Homoharringtonine

It is an alkaloid derived from the plant *Cephalotoxus fortunei*. It has anti-tumor activity and usually inhibits the viral protein translation. In past years, it has been used against the herpes virus, rhabdovirus, murine hepatitis virus, coronaviruses, echovirus 1 and hepatitis B virus [67, 73]. By mechanism, HHT is found to bind and interact with the A-site of peptidyl transferase of the ribosomes and inhibits the translation of proteins [63]. Omacetaxine, a semi-synthetic homoharringtonine is FDA approved drug for the treatment of chronic myeloid leukemia [74]. In vitro experiments showed that it is also effective to reduce the SARS-CoV-2 infection [65].

4.1.7. Ivermectin

This is an FDA-approved drug that is antiparasitic and possesses the potential to be adopted for neglected topical diseases but is still not approved for the treatment of any viral disease. The proposed mechanism of action of ivermectin suggests the inhibition of a crucial intracellular transport procedure that is utilized by the virus to increase the infection through the suppression of the host’s antiviral response i.e. inhibition of the host importin alpha/beta-1 nuclear transport proteins [75]. Analysis of nuclear transport inhibitory activity of ivermectin suggests it is equally effective as well, in the case of SARS-CoV-2 treatment [76].

4.1.8. Favipiravir

It is another promising drug to treat the infection of coronavirus and is a purine nucleic acid analog. Favipiravir is an antiviral candidate according to various clinical trials and is found to be an RNA-dependent RNA polymerase inhibitor. In cells, the phosphorylated form of Favipiravir is proved to be activated (Favipiravir-RTP), which inhibits the polymerase activity of viral RNA [77]. Mechanistically, the medication is not fully known, but studies reveal that it acts as a substrate of
the viral RNA polymerase that leads to the conversion of an active phosphoribosylated state. The drug is believed to obstruct the genomic RNA synthesis of the virus as a chain terminator [78]. It is found to be an RdRp inhibitor with a prior intervention in the Ebola virus and is now indicated to prevent the SARS-CoV-2 replication with an EC\textsubscript{50} value to be 61.88 \(\mu\text{M} \) [62].

4.1.9. Atazanavir/ritonavir

A deeper analysis of the coronavirus has revealed that Main protease (M\textsuperscript{pro}) or the 3-Chymotrypsin like Protease is a proteolytic enzyme that acts pivotally to cleave the replicase polyprotein 1ab in SARS-CoV-2. Orf1ab of the viral RNA genome is responsible for the translation of M\textsuperscript{pro} that is also known as non-structural protein 5 (nsp5) and consists of 306 amino acids [79]. Furthermore, it has been recognized that there are 12 nsps (nsp4 and nsp6 to nsp16) involved in viral replication and its assembly, M\textsuperscript{pro} is found to release these 12 nsps by cleaving the replicase polyprotein at 11 specific sites. Primarily, the enzyme is a dimer in structure with three domains on each monomer. M\textsuperscript{pro} is a promising drug target due to its functional significance in the SARS-CoV-2 life cycle and the presence of distinct recognition sites which are not possessed by human proteases [62]. In this regard, Fintelman-Rodrigues along with co-workers recognized the potential of atazanavir alone and in combination with ritonavir for COVID-19 treatment [80]. Molecular dynamics and molecular docking revealed that atazanavir possesses the potential to target the active site of M\textsuperscript{pro}. Both the drugs were also analyzed for their potential against SARS-CoV-2 in human epithelial pulmonary cell lines and Vero E6 cells. The drugs were found to inhibit the SARS-CoV-2 in the two cell lines vigorously [62].
4.1.10. EK1C4

SARS-CoV-2 mediated cell-cell fusion is potentially inhibited by the derivatives of EK-1 that were designed by covalently linking with palmitic (EK1P) and cholesterol (EK1C) with their IC_{50} values as 69.2 nM and 48.1 nM, respectively. Based on the success, further peptides were created (EK1C1 to EK1C7) with PEG-based spacers and glycine/serine-based linkers (GSG). Among them, EK1C4 is considered as the most potent lipopeptide, having five optimal residues linker/spacer GSGSG-PGE4 and shown to possess potential activity against live SARS-CoV-2 infection and its pseudovirus infection with IC_{50} value to be 36.5 nM and 15.8 nM, respectively. Hence, EK1C4 can be considered as a promising drug candidate against COVID-19 [62].

4.2. Indirect therapeutic drugs against the virus

These drugs help the immune system fight against the virus but do not directly inhibit viral replication. They are more preferred than direct therapeutic drugs as they do not induce resistance to the virus.

4.2.1. Tocilizumab

Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody, directed against soluble and membrane-bounded interleukin-6 (IL-6) receptors [81]. Monoclonal antibodies provide a quick and better protective effect against these viruses as compared to vaccines [1]. TCZ was used for the treatment of many life-threatening cytokine release syndromes including severe rheumatoid arthritis and giant cell arteritis [82]. It is used to treat the severe patients of COVID-19 as it helps to reduce the level of C reactive proteins [83]. Furthermore, treatment with TCZ showed clinical benefits where patients are at high risk of cytokine storm [84]. It is officially approved for the treatment of COVID-19 in many countries including Italy, Pakistan and China [85, 86]. The aim
of using TCZ is to reduce the risk of invasive ventilation or death in a cohort of severe COVID-19 patients.

4.2.2. Chloroquine

It is an aminoquinoline and a broad-spectrum antiviral drug that is widely used as an autoimmune and anti-malarial drug [87]. It is used for the treatment of COVID-19 as it affects the glycosylation of ACE2 cell receptor which is used by the virus to enter the host cell [88]. It also blocks the viral infection by increasing the endosomal pH required for viral cell fusion. It was highly effective against SARS-CoV and now it is potentially used for the treatment of COVID-19 [52, 89]. Some countries have officially approved the use of chloroquine against SARS-CoV-2 [90, 91]. Chloroquine is found to accumulate itself in Golgi-like organelles and those vesicles which are acidic; for instance the endosomes and lysosomes, in its unprotonated state. These destinations ionized the chloroquine which in turn increases their pH and inactivates various proteolytic enzymes. On the other hand, the virus demands the acidic surroundings to enter, replicate, and cause infection in the endosome-lysosome. Hence, an increase in pH can efficiently prevent viral entry and replication [92]. The promising drug is also found to intervene in the interaction between ACE-2 receptors and viral spike proteins that is vital to allow the entry of the virus into the cell, indirectly. The affinity to SARS-CoV-1 S protein is decreased when chloroquine hinders the Golgi-mediated glycosylation of ACE-2 at N-terminal. Therefore, delicate interaction prevents viral entry into the cell [62].

4.2.3. Leronlimab

This is another suggested humanized monoclonal antibody that is found to bind CC-chemokine receptor-5 (CCR5). Finite evidence is present to suggest leronlimab as an optimistic approach to
treat infection by a coronavirus [93] but still not investigated completely to prove its potential to manage the COVID-19 [78].

4.2.4. Camostat

Apart from ACE-2 receptors, SARS-CoV-2 is also assisted by transmembrane protease serine 2 (TMPRSS2), which is encoded by the TMPRSS2 gene and is a host cellular protease. It is predominantly found in the cell membrane of the epithelial lung cells and assists the spike protein priming that fuses the membranes of the cell and that of the virus, which is also considered as the crucial step for viral entry. Recently, this entry is found to prevent by camostat, an inhibitor of TMPRSS2 [94]. It is a serine protease inhibitor and is previously used to treat pancreatitis and was recently found to inhibit the SARS-CoV-2 via TMPRSS2 inhibition. Currently, under clinical trial, camostat might prove to be an efficient drug to tackle COVID-19 [62].

4.2.5. Nafamostat

It is another serine protease inhibitor and acts as an anticoagulant. It was shown to bind to the TMPRSS2-a transmembrane protease and prevents the SARS-CoV-2 entry into the cell with an EC$_{50}$ value to be 22.50 µM [89]. Nafamostat can also be considered as a therapeutic drug against COVID-19 [62].

4.2.6. E-64-d

This is a cathepsin L inhibitor and assists the camostat to inhibit the entry of SARS-CoV-2 [95]. Cathepsins are primarily cysteine proteases and are of immense importance during the catabolism of protein in lysosomes and endosomes. Cathepsin L is also fundamental for the entry of SARS-CoV into the host cell. Once inside the endosomes, cathepsin L activates the viral spike protein and hence the release of viral genetic material into the cytoplasm after fusion of endosomal
membranes and the virus [62]. E-64-d is a covalent cathepsin inhibitor and is found to contain an epoxide ring that forms the covalent bond at the catalytic site once undergone nucleophilic attack by Cys-SH [96].
| Type of therapeutic drugs | Therapeutic drugs | Bioactivity                                                                 | Clinical phase                                                                 | References                  |
|---------------------------|-------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------------------------|
| Direct therapeutic drugs against the virus | Remdesivir       | An adenosine analog that inhibits the viral replication                      | Under 4th phase of the clinical trial against SARS-CoV-2                      | [5, 58, 59, 89]             |
|                           | Lopinavir         | Works as a protease inhibitor                                                | Approved for HIV infection                                                   | [52, 65]                   |
|                           | Emetine           | Works as a protein synthesis inhibitor                                      | Approved for severe amoebiasis in China                                      | [65]                        |
| Drug           | Action                                                                 | Status                                                                 | Reference |
|---------------|------------------------------------------------------------------------|----------------------------------------------------------------------|-----------|
| Homoharringtonine | Inhibit the replication of SARS-CoV-2                                  | Approved by FDA to treat chronic myeloid leukemia                     | [65, 73] |
|               |                                                                        | Under clinical trial for SARS-CoV-2                                   |           |
| Ivermectin    | Inhibition of the host importin alpha/beta-1 nuclear transport proteins | Still not approved for the treatment of any viral disease             | [75]      |
| Favipiravir    | It is a purine nucleic acid analog                                     | Another promising option                                              | [77]      |
| Aloxistatin    | It is a cysteine protease inhibitor of cathepsins and calpains         | Promising drug candidate                                               | [63]      |
| Viracept       | Targets the SARC-CoV-2 spike glycoprotein                               | Promising drug candidate                                               | [63]      |
| Indirect therapeutic drugs against the virus | Atazanavir/Ritonavir | Possess potential activity against live SARS-CoV-2 infection and its pseudovirus infection | EKIC4 | Possess potential activity against live SARS-CoV-2 infection and its pseudovirus infection | Chloroquine | Interferes the mechanism of Glycosylation in cellular receptors | Tocilizumab | A monoclonal antibody used to reduce the level of C-reactive protein in severe patients |
|---|---|---|---|---|---|---|---|---|
| inhibits the S-o and S-n-mediated cell fusion | Target the active site of M\textsuperscript{pro} | Promising drug candidate | Promising drug candidate | Approved to used against SARS-CoV-2 in some countries | Approved for the treatment of COVID-19 in some countries | [62] | [52] | [85, 97] |
| Faheem et al., 2020);[80] | | | | | | | | |
| **Leronlimab** | A humanized monoclonal antibody, bind CC-chemokine receptor-5 (CCR5) | Still not investigated completely to prove its potential to manage the COVID-19 | [93, 78] |
| **Camostat** | Inhibit the SARS-CoV-2 via TMPRSS2 inhibition | Promising drug candidate | [94, 62] |
| **E-64-d** | Cathepsin L inhibitor | Promising drug inhibitor | [95, 96] |
| **Nafamostat** | Bind to the TMPRSS2 | Promising drug candidate | [62, 89] |

### 4.3 Vaccines against the SARS-CoV-2 virus
The COVID-19 pandemic is continued in its journey to conquer all projections and devastations across the globe even after many months of its cradle. Studies reveal the existence of antibodies against coronavirus as the primary stimulus of protection. This makes the interaction of virus either naturally or by vaccination, a crucial element for the occurrence of population immunity to resist the corona pandemic. However, the mechanism of enduring immunity is still not recognized fully [98].

Vaccines appear to be the most auspicious way to alleviate the new viral strains and to reduce the prolonged incubations and outrageous prevalence of COVID-19. The general strategy to design a vaccine involves the antigen, the adjuvant, the manufacturing system and the functioning strategy to deliver it. The protein structure of the virus and its genome sequence was made accessible in a remarkably short duration, to boost the development of attenuated or inactivated viral vaccines and other treatments along with epitope mapping and bioinformatics predictions [99]. Myriads of efforts are on the way to vaccine development with the majority of the candidate vaccines focusing upon the S-protein of SARS-CoV-2 and based on protein sub-unit, live attenuated virus or inactivated one, nanoparticles, viral vector, RNA and DNA, etc., each possessing its obstacles and precedence. Apart from this, researchers are also considering some adjuvants like CpG 1018 (Dynavax) and AS03 (GSK), etc. to escalate the immunogenicity [100]. COVID-19-associated hospitalization was notably reduced due to corona vaccines and hopes are there to observe a significant turn down in post-corona issues and even deaths. Like a shred of evidence, it was observed that adult recipients of Moderna and Pfizer-BioNTech vaccines showed 94% effectiveness in the case of complete vaccination while partial ones received 64% efficacy with 65+ years of age [101].
United Kingdom was the first country in this regard to execute the vaccination program against COVID-19 on 8th December 2020 and approved the emergency use of Pfizer-BioNTech that is an mRNA vaccine. Later on, it was enlarged to take in the Oxford-AstraZeneca as well which is an adenovirus vector vaccine. Initially, vaccination was given to older people of age ≥ 80, frontline workers and then extended to other age groups [102]. However, some post-corona vaccine adverse effects were observed that include systematic effects like chills, fever, fatigue and headache, etc. and local ones that involve itching, bruising, redness and swelling, etc. Many patients experience some of these clinical symptoms at the injection site that often vanish after a few days. Quiet occasionally, if symptoms do not get better then SIRVA—a shoulder injury related to vaccine administration may occur that is a rare condition due to an improper injection technique [103]. Despite that, the worldwide administration of COVID-19 vaccination at a massive scale has decreased the emerging and inauspicious events. Many options for vaccine development are under consideration to target the proteins and virions of the virus [31, 104] as shown in Table 2.
Table 2. Types of vaccines against SARS-CoV-2

| Type of vaccine                  | Bioactivity          | Advantages                                      | Disadvantages                                      | References |
|---------------------------------|----------------------|-------------------------------------------------|---------------------------------------------------|------------|
| DNA & RNA Vaccine               | Targets the S Protein| • Easy manipulation<br>• Immunogenic<br>• Rapid production | • Safety issues<br>• Efficient delivery system requid | [31, 104]  |
| Viral vector based vaccine      | Targets the S Protein| • Excellent clinical and preclinical results<br>• Successful against MERS-CoV | • Negative effect of vector can disturb viral effectiveness | [31, 104]  |
| Inactivated vaccine             | Targets the whole virion | • Easy process | • Large amount of infectious | [31, 104]  |
In this review, the progressive literature review has been used to summarize the innate and adaptive immune response and the availability of potential therapeutic agents as well as vaccines against SARS-CoV-2. Type 1 Interferon, the innate immunomodulatory molecules, fight against SARS-CoV-2 by inhibiting viral replication at an early stage. However, adaptive immunity is also

| Live attenuated vaccine | Targets the whole virion | • Excellent in induction of T and B cell response | • Not suitable | [31, 104] |
|-------------------------|--------------------------|---------------------------------|----------------|----------|
|                         |                          | • Simple process                 | • Risk of reversion to a viral strain |          |
|                         |                          |                                 | • Safety issues |          |
| Recombinant protein vaccine | Targets the S Protein | • No infectious virus required | • Limited production | [104]    |
|                         |                          | • Adjuvants may be used          |                |          |

5. Conclusion

In this review, the progressive literature review has been used to summarize the innate and adaptive immune response and the availability of potential therapeutic agents as well as vaccines against SARS-CoV-2. Type 1 Interferon, the innate immunomodulatory molecules, fight against SARS-CoV-2 by inhibiting viral replication at an early stage. However, adaptive immunity is also
observed in patients where the production of antibodies and antigen-specific B cells reduces the viral infection. Furthermore, direct and indirect therapeutic drugs are evaluated against SARS-CoV-2. Remdesivir, Lopinavir, Emetine, and Homoharringtonine are the potentially available direct therapeutic drugs that have been used for the treatment of COVID-19. While Chloroquine and Tocilizumab are the indirect therapeutic drugs used to enhance the immune response against the virus. Indirect therapeutic drugs are comparatively more efficient than direct therapeutic drugs as they do not cause drug resistance in the virus. There are various vaccine candidates under the consideration of many research institutes and pharmaceutical companies around the globe to develop an optimum vaccine against COVID-19. Among them, the worth mentioning is the Moderna and Pfizer-BioNTech with an mRNA platform and having a significant success rate of up to 90%. Despite the rapid progress, some inauspicious effects of the vaccination were observed like headache, pain and fatigue. However, the trial assay sensitivity supported the mRNA vaccine. Yet numerous unknowns continue to prosper this devastating pandemic. Undefined virus mutation is the most significant one and if it occurred in the spike protein, would lead to streamlining analysis of genome sequence to perpetuate sustainable vaccine

**Conflict of interest**

The authors have no conflict of interest.

**References**

1. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. *J Med Virol*. 2020;92(4):424-432. doi:10.1002/jmv.25685
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
3. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. *N Engl J Med*. 2003;348(20):1986-1994. doi:10.1056/NEJMoa030685

4. World Health Organization. Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 17 January 2020. *WHO - Interim Guid.* Published online 2020.

5. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med*. Published online 2020. doi:10.1056/NEJMoa2001191

6. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res.* Published online 2020.

7. Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. *Transfus Med Rev.* Published online 2020.

8. Organization WH. *Weekly Operational Update on COVID-19, 23 October 2020.*; 2020.

9. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* Published online 2020. doi:10.1056/NEJMoa2002032

10. Donnelly CA, Fisher MC, Fraser C, et al. Epidemiological and genetic analysis of severe acute respiratory syndrome. *Lancet Infect Dis.* Published online 2004. doi:10.1016/S1473-3099(04)01173-9

11. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. *Clin Immunol.* Published online 2020. doi:10.1016/j.clim.2020.108448

12. Zhang J, Jin D, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy Eur J Allergy Clin Immunol.* Published online 2020. doi:10.1111/all.14238

13. Jiang X, Rayner S, Luo MH. Does SARS-CoV-2 has a longer incubation period than SARS and MERS? *J Med Virol.* 2020;92(5):476-478. doi:10.1002/jmv.25708

14. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* Published online 2020. doi:10.1007/s00134-020-05991-x

15. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. *J Med Virol.* Published online 2020. doi:10.1002/jmv.25748

16. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment. *Cureus.* Published online 2020. doi:10.7759/cureus.7355

17. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. 2020;2019(Xx Xxxx):4-10. doi:10.1093/cid/ciaa248

18. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and
immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6(1):25359. doi:10.1038/srep25359

19. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585

20. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of the Science. Immunity. Published online 2020. doi:10.1016/j.immuni.2020.05.002

21. Zhou Y, Han T, Chen J, et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19. Clin Transl Sci. Published online 2020. doi:10.1111/cts.12805

22. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-423.

23. Zhou P, Yang X Lou, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. Published online 2020. doi:10.1038/s41586-020-2012-7

24. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. Published online 2020. doi:10.1056/NEJMoa2001017

25. DeDiego ML, Álvarez E, Almazán F, et al. A Severe Acute Respiratory Syndrome Coronavirus That Lacks the E Gene Is Attenuated In Vitro and In Vivo. J Virol. Published online 2007. doi:10.1128/jvi.01467-06

26. Hussain S, Pan J, Chen Y, et al. Identification of Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe Acute Respiratory Syndrome Coronavirus. J Virol. Published online 2005. doi:10.1128/jvi.79.9.5288-5295.2005

27. Trougakos IP, Stamatelopoulos K, Terpos E, et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021;28(1):1-18. doi:10.1186/s12929-020-00703-5

28. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155-170. doi:10.1038/s41579-020-00468-6

29. MALIK YA. Properties of Coronavirus and SARS-CoV-2. Lancet Infect Dis. 2020;20(11):1-9.

30. Ni L, Ye F, Chen ML, et al. Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2. medRxiv. Published online 2020:2020.03.17.20036640. doi:10.1101/2020.03.17.20036640

31. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific J Allergy Immunol. Published online 2020. doi:10.12932/AP-200220-0772

32. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell.
33. Baccala R, Gonzalez-Quintial R, Lawson BR, et al. Sensors of the innate immune system: Their mode of action. Nat Rev Rheumatol. Published online 2009. doi:10.1038/nrrheum.2009.136

34. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523.

35. Ivashkiv LB, Donlin LT. Regulation of type i interferon responses. Nat Rev Immunol. Published online 2014. doi:10.1038/nri3581

36. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. Published online 2020. doi:10.1016/j.cell.2020.04.026

37. D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transplant. Published online 2020.

38. Cecere TE, Todd SM, LeRoith T. Regulatory T cells in arterivirus and coronavirus infections: Do they protect against disease or enhance it? Viruses. Published online 2012. doi:10.3390/v4050833

39. Maloir Q, Ghysen K, von Frenckell C, Louis R, Guiot J. [Acute respiratory distress revealing antisynthetase syndrome]. Rev Med Liege. Published online 2018.

40. Kumar S, Nyodu R, Maurya VK, Saxena SK. Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection. In: Coronavirus Disease 2019 (COVID-19). Springer; 2020:43-53.

41. Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020;9(1):558-570.

42. Ahmadpoor P, Rostaing L. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. Transpl Int. Published online 2020. doi:10.1111/tri.13611

43. Rate CF. Characteristics of Patients Dying in Relation to COVID-19 in Italy Onder G, Rezza G, Brusaferro S. JAMA Publ online March. 2020;23.

44. Liu W, Fontanet A, Zhang PH, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792-795.

45. Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82-92.

46. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. Published online 2020.

47. Shin HS, Kim Y, Kim G, et al. Immune responses to Middle East respiratory syndrome
coronavirus during the acute and convalescent phases of human infection. Clin Infect Dis. 2019;68(6):984-992.

48. Prompetchara E, Ketloy C, Tharakhet K, et al. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. PLoS One. 2021;16(3 March):1-16. doi:10.1371/journal.pone.0248007

49. Zhang Y, Gargan S, Lu Y, Stevenson NJ. An overview of current knowledge of deadly covs and their interface with innate immunity. Viruses. 2021;13(4). doi:10.3390/v13040560

50. Santarpia JL, Rivera DN, Herrera VL, et al. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep. 2020;10(1):1-8.

51. Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. Published online 2020:102434.

52. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1-14.

53. Barton C, Kouokam JC, Lasnik AB, et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014;58(1):120-127.

54. Ma-Lauer Y, Zheng Y, Malešević M, von Brunn B, Fischer G, von Brunn A. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res. 2020;173:104620.

55. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol. 2000;81(10):2341-2364.

56. Khan S, Siddique R, Shereen MA, et al. Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: biology and therapeutic options. J Clin Microbiol. 2020;58(5).

57. Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14(4):397-412.

58. Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.

59. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci. 2020;117(12):6771-6776.

60. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773-4779. doi:10.1074/jbc.AC120.013056
61. Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. ChemBioChem. 2020;21(5):730-738. doi:10.1002/cbic.202000047

62. Faheem, Kumar BK, Sekhar KVGC, et al. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. Bioorg Chem. 2020;104(June):104269. doi:10.1016/j.bioorg.2020.104269

63. Yousefi H, Mashouri L, Okpechi SC, Alahari N, Alahari SK. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. Biochem Pharmacol. 2021;183(October 2020):114296. doi:10.1016/j.bcp.2020.114296

64. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2).

65. Choy KT, Wong AYL, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. Published online 2020:104786.

66. Yang CW, Peng TT, Hsu HY, et al. Repurposing old drugs as antiviral agents for coronaviruses. Biomed J. Published online 2020.

67. Andersen PI, Krpina K, Ianevski A, et al. Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine. Viruses. 2019;11(10):964.

68. Valadão ALC, Abreu CM, Dias JZ, et al. Natural plant alkaloid (emetine) inhibits HIV-1 replication by interfering with reverse transcriptase activity. Molecules. 2015;20(6):11474-11489.

69. Khandelwal N, Chander Y, Rawat KD, et al. Emetine inhibits replication of RNA and DNA viruses without generating drug-resistant virus variants. Antiviral Res. 2017;144:196-204.

70. Mukhopadhyay R, Roy S, Venkatadri R, et al. Efficacy and mechanism of action of low dose emetine against human cytomegalovirus. PLoS Pathog. 2016;12(6).

71. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574.

72. Shen L, Niu J, Wang C, et al. High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. J Virol. 2019;93(12):e00023-19.

73. Dong HJ, Wang ZH, Meng W, et al. The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo. Viruses. 2018;10(11):601.

74. Quintás-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009;115(23):5382-5393.

75. Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets
the host nuclear transport importin α/β1 heterodimer. *Antiviral Res.* 2020;177:104760. doi:10.1016/j.antiviral.2020.104760

76. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 2020;178(March):3-6. doi:10.1016/j.antiviral.2020.104787

77. Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. *Sci Rep.* 2021;11(1):1-11. doi:10.1038/s41598-021-90551-6

78. Ita K. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. *Arch Med Res.* 2021;52(1):15-24. doi:10.1016/j.arcmed.2020.09.010

79. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. *Nature.* 2020;579(7798):265-269. doi:10.1038/s41586-020-2008-3

80. Fintelman-Rodrigues N, Sacramento CQ, Lima CR, et al. Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production. *bioRxiv.* Published online 2020. doi:10.1101/2020.04.04.020925

81. Consortium I 6 RMRA (IL6R M. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet.* 2012;379(9822):1214-1224.

82. Kotch C, Barrett D, Teachtey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. *Expert Rev Clin Immunol.* 2019;15(8):813-822.

83. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. *J Med Virol.* Published online 2020.

84. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol.* Published online 2020.

85. Hussain M, Zaman S, Bari A. Guidelines for the Treatment of Severe and Critical Cases of COVID-19. Published online 2020.

86. Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report. *Chest.* Published online 2020.

87. Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. *Cell Res.* 2013;23(2):300-302.

88. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG. Virol. *Chloroquine is a potent Inhib SARS coronavirus Infect spread J.* 2005;2:69.

89. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(3):269-271.

90. Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease
2019 (COVID-19): chloroquine or hydroxychloroquine. *Int J Antimicrob Agents*. 2020;105945(10.1016).

91. Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res*. Published online 2020;104762.

92. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. *Pharmaco Res Perspect*. 2017;5(1):1-13. doi:10.1002/prp2.293

93. Yang B, Fulcher JA, Ahn J, et al. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab. *Clin Infect Dis*. 2020;90095(October):1-8. doi:10.1093/cid/ciaa1583

94. Hofmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052

95. Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J Med Virol*. 2020;92(6):595-601. doi:10.1002/jmv.25726

96. Cannalire R, Stefanelli I, Cerchia C, Beccari AR, Pelliccia S, Summa V. Sars-cov-2 entry inhibitors: Small molecules and peptides targeting virus or host cells. *Int J Mol Sci*. 2020;21(16):1-27. doi:10.3390/ijms21165707

97. Sciascia S, Aprà F, Baffà A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19. *Clin Exp Rheumatol*. 2020;38(3):529-532.

98. Bobdey S, Kaushik SK, Menon AS. The conundrum of two-dose interval of ChAdOx1 nCOV-19 corona virus vaccine: Way ahead. 2020;(January).

99. Shin MD, Shukla S, Chung YH, et al. COVID-19 vaccine development and a potential nanomaterial path forward. *Nat Nanotechnol*. 2020;15(8):646-655. doi:10.1038/s41565-020-0737-y

100. Rather RA, Islam T, Rehman IUL, Pandey D. Development of Vaccine Against Coronavirus Disease 2019 (Covid-19) in India. *Asian J Adv Med Sci*. 2021;3(2):13-21.

101. Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥ 65 Years —January-March 2021. *Mmwr*. 2021;70(18):674-679.

102. Bernal JL, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. *BMJ*. 2021;373. doi:10.1136/bmj.n1088

103. Chuaychoosakoon C, Parinyakhup W, Tanutit P, Maliwankul K. Shoulder injury related to Sinovac COVID-19 vaccine: A case report. *Ann Med Surg*. 2021;68(July):102622. doi:10.1016/j.amsu.2021.102622
104. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. *Immunity*. Published online 2020.